Tasca Therapeutics
Cambridge, US · Founded 2021 · 3 known investors
Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.
Biotech
Founders & leadership
PT
Praveen TipirneniNamed on SEC filing
DF
David FallaceNamed on SEC filing
SL
MA
Michael AbermanNamed on SEC filing
DK
Drew KingNamed on SEC filing
MC
Milenko CicmilNamed on SEC filing
XW
Xu WuNamed on SEC filing
Investors · 3
Funding
SEC filings, press & company announcements$52M disclosed across 1 round · 2024
- $52MSeries ADec 2024 · 2 sourcesSource ↗
▶$48.1MraisedDec 2025 · 9 investors · BiotechnologyRule 506(b)
▶$48.1MraisedDec 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Praveen TipirneniDirector
- David FallaceDirector
- Seth LieblichDirector
- Michael AbermanDirector
- Drew KingExecutive Officer
- Milenko CicmilExecutive Officer, Director
- Xu WuDirector
- Offering amount
- $70.2M
- Amount sold
- $48.1M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Tasca Therapeutics do?
- Unlocking post-translational protein modification using chemical biology and computational approaches to develop drugs for previously undruggable oncology targets.
- Who are Tasca Therapeutics's investors?
- Tasca Therapeutics's investors include 8VC, Cure Ventures, SOSV.
- How much funding has Tasca Therapeutics raised?
- Tasca Therapeutics has disclosed $52M raised across 1 round.
- Where is Tasca Therapeutics headquartered?
- Tasca Therapeutics is headquartered in Cambridge, US.